The results showed that the use of anti-PVRIG mAb significantly inhibited tumor growth in Rag1−/− mice compared to those treated with control antibody (P < 0.001; Fig. 6h), suggesting that anti-PVRIG mAb was effective even in the absence of adaptive immunity. The gene discussed is PVRIG; the disease is neoplasm.